All In Biotech

Free tool

FAERS Monitor: Lokelma

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 207078 or its brand name (Lokelma, Sodium Zirconium Cyclosilicate). Reports on generic versions are filed under their own applications.

Reports

4,008

Serious

3,277

82% of reports

Hospitalization

1,089

Death reported

1,441

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • death1,159
  • blood potassium increased206
  • hyperkalaemia186
  • diarrhoea180
  • constipation127
  • off label use127
  • cardiac failure95
  • nausea94
  • renal failure94
  • vomiting89
  • acute kidney injury84
  • pneumonia80
  • chronic kidney disease79
  • renal impairment78
  • drug ineffective77

Reports by year received

View as table
YearReports
201810
2019112
2020200
2021262
2022387
2023541
2024828
2025863
2026805

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,050,151 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
blood potassium increasedSignal20667.559.013,260
hyperkalaemiaSignal18628.024.34,795
deathSignal1,1597.16.76,281
cardiac failureSignal956.25.1412
chronic kidney diseaseSignal795.54.4284
renal impairmentSignal784.93.9237
renal failureSignal943.73.0185
constipationSignal1273.12.6175
acute kidney injurySignal842.92.3102
diarrhoea1801.51.327
pneumonia801.31.05
vomiting891.00.80
off label use1270.80.610
nausea940.60.522
drug ineffective770.30.2128

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.